TRI-1144: Phase I data

In the double-blind, placebo-controlled Phase I trial (TRI-1144-101) in 24 healthy volunteers, TRI-1144 was well tolerated at 4 doses ranging from 25 to 250 mg. The plasma half-life of the compound ra...